isunakinra + PD-(L)1 inhibitor

**Isunakinra + PD-(L)1 inhibitor** is a combination therapy currently under clinical investigation for solid tumors and metastatic cancers. Isunakinra is a recombinant protein that functions as a high-potency interleukin-1 receptor (IL1R1) inhibitor, blocking both IL-1α and IL-1β from activating the receptor. PD-(L)1 inhibitors, such as pembrolizumab or nivolumab, are immune checkpoint inhibitors that block the PD-1/PD-L1 pathway to restore anti-tumor T cell activity. The combination aims to synergistically modulate the tumor microenvironment: isunakinra counteracts chronic inflammation and immunosuppression driven by IL-1, while the PD-(L)1 inhibitor enhances T cell mediated immune responses against tumors. The strategy targets multiple immune escape mechanisms, with clinical trials reporting favorable safety and pharmacokinetic profiles and early signals of activity in certain colorectal cancer subsets (MSS, TMB-high, KRAS-mutant)[1][2][7][8][9].